Oral semaglutide lowers heart failure events in people with type 2 diabetes and existing heart failure without increasing adverse events.
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results